Goodenow B - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.

Bissonnette RP, Cesario RM, Goodenow B, Shojaei F, Gillings M. Bissonnette RP, et al. Among authors: goodenow b. BMC Cancer. 2021 Aug 30;21(1):969. doi: 10.1186/s12885-021-08702-x. BMC Cancer. 2021. PMID: 34461854 Free PMC article.

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors.

Shojaei F, Goodenow B, Lee G, Kabbinavar F, Gillings M. Shojaei F, et al. Among authors: goodenow b. Front Oncol. 2022 Jan 7;11:768685. doi: 10.3389/fonc.2021.768685. eCollection 2021. Front Oncol. 2022. PMID: 35070972 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2 results

Search Page

Filters